Clinical and FDG-PET/CT Suspicion of Malignant Disease: Is Biopsy Confirmation Still Necessary?
18F-FDG
PET-CT
biopsy
cancer
malignancy
tumors
Journal
Diagnostics (Basel, Switzerland)
ISSN: 2075-4418
Titre abrégé: Diagnostics (Basel)
Pays: Switzerland
ID NLM: 101658402
Informations de publication
Date de publication:
20 Mar 2021
20 Mar 2021
Historique:
received:
19
02
2021
revised:
13
03
2021
accepted:
17
03
2021
entrez:
3
4
2021
pubmed:
4
4
2021
medline:
4
4
2021
Statut:
epublish
Résumé
Biopsy of This single-center retrospective study included 83 patients who had undergone FDG-PET/CT within 60 days before CT- or ultrasonography-guided tissue sampling and whose request form for CT- or US-guided tissue sampling requested mutation analyses. The latter implies a high clinical suspicion of active malignant disease. The nature of each biopsied lesion was determined based on the results of the pathological analysis and/or clinical and imaging follow-up of at least 12 months. In total, eighty-eight FDG-avid lesions were biopsied. The PPV of FDG-PET/CT for malignancy was 98.9% (95% CI: 93.8-99.8%). For patients with an oncological history, the PPV was 98.7% (95% CI: 92.9-99.8%), and for patients with no oncological history, the PPV was 100% (95% CI: 74.1-100.0%). There was no significant difference between the PPV of the group with and without an oncological history ( Although the PPV of FDG-PET/CT for malignancy in patients with a clinical suspicion of active malignant disease is high, biopsy remains recommended to avoid inappropriate patient management due the non-negligible chance of dealing with FDG-avid benign disease or unexpected malignancies.
Sections du résumé
BACKGROUND
BACKGROUND
Biopsy of
METHODS
METHODS
This single-center retrospective study included 83 patients who had undergone FDG-PET/CT within 60 days before CT- or ultrasonography-guided tissue sampling and whose request form for CT- or US-guided tissue sampling requested mutation analyses. The latter implies a high clinical suspicion of active malignant disease. The nature of each biopsied lesion was determined based on the results of the pathological analysis and/or clinical and imaging follow-up of at least 12 months.
RESULTS
RESULTS
In total, eighty-eight FDG-avid lesions were biopsied. The PPV of FDG-PET/CT for malignancy was 98.9% (95% CI: 93.8-99.8%). For patients with an oncological history, the PPV was 98.7% (95% CI: 92.9-99.8%), and for patients with no oncological history, the PPV was 100% (95% CI: 74.1-100.0%). There was no significant difference between the PPV of the group with and without an oncological history (
CONCLUSION
CONCLUSIONS
Although the PPV of FDG-PET/CT for malignancy in patients with a clinical suspicion of active malignant disease is high, biopsy remains recommended to avoid inappropriate patient management due the non-negligible chance of dealing with FDG-avid benign disease or unexpected malignancies.
Identifiants
pubmed: 33804753
pii: diagnostics11030559
doi: 10.3390/diagnostics11030559
pmc: PMC8003997
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Radiographics. 2016 Mar-Apr;36(2):481-96
pubmed: 26963458
Semin Nucl Med. 2007 Nov;37(6):400-19
pubmed: 17920348
Ann Nucl Med. 2001 Dec;15(6):471-86
pubmed: 11831394
Semin Nucl Med. 2007 May;37(3):206-22
pubmed: 17418153
J Cancer Res Ther. 2017 Oct-Dec;13(6):1000-1006
pubmed: 29237966
Mol Imaging Radionucl Ther. 2018 Oct 09;27(3):126-132
pubmed: 30317849
Acad Radiol. 2014 Feb;21(2):232-49
pubmed: 24439337
Psychooncology. 2012 Jan;21(1):1-10
pubmed: 22905349
Cancer Imaging. 2012 Oct 16;12:437-46
pubmed: 23092816
Eur J Nucl Med Mol Imaging. 2015 Feb;42(2):328-54
pubmed: 25452219
AJR Am J Roentgenol. 2013 Aug;201(2):433-8
pubmed: 23883226
Eur Radiol. 2019 Jul;29(7):3372-3378
pubmed: 30666444
Cancers (Basel). 2014 Sep 29;6(4):1821-89
pubmed: 25268160
Pers Soc Psychol Bull. 2015 Nov;41(11):1551-9
pubmed: 26338852
AJR Am J Roentgenol. 2007 Nov;189(5):1203-10
pubmed: 17954662